{"classes":[{"categories":[{"measurements":[{"comment":"only 1 participant assessed","groupId":"OG000","spread":"NA","value":"14998.00"},{"groupId":"OG001","spread":"50.46","value":"12929.22"}]}],"title":"Bendamustine; n=1, 13"},{"categories":[{"measurements":[{"comment":"no participants assessed","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"1.80","value":"1336.89"}]}],"title":"Metabolite M3; n=0, 2"},{"categories":[{"measurements":[{"comment":"no participants assessed","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"no participants assessed","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"Metabolite M4; n=0, 0"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Bendamustine 90 mg/m\\^2 administered as an intravenous (IV) infusion over 60 minutes on Days 1 and 2 of a 21-day Induction cycle, with delays up to 2 weeks for neutrophil and platelet count recovery, for up to a 35-day cycle.","id":"OG000","title":"Bendamustine 90 mg/m^2"},{"description":"Bendamustine 120 mg/m\\^2 administered as an IV infusion over 60 minutes on Days 1 and 2 of each 21-day cycle (maximum of 12 total cycles), with delays up to 2 weeks for neutrophil and platelet count recovery, for up to a 35-day cycle.","id":"OG001","title":"Bendamustine 120 mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The pharmacokinetic analysis set included all participants who were in the safety analysis set (ie, those treated at any dose of bendamustine) who had valid pharmacokinetic data; n=number of participants with valid data for this assessment.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Day 1: before infusion, immediately following the infusion, and 3, 6, 10(±2), and 24 hours after the start of infusion. The 24-hour postinfusion sample was obtained before the start of the infusion on Day 2.","title":"Area Under the Plasma Drug Concentration by Time Curve From Time 0 Until 24 Hours After Study Drug Administration (AUC0-24) for Bendamustine and Its Metabolites (M3 and M4)","type":"SECONDARY","unitOfMeasure":"ng*hr/mL"}